Article Text

PDF
SAT0249 Predictors of Response To Methotrexate in Patients with Eosinophilic Fasciitis
  1. W.A. Sifuentes Giraldo1,
  2. D. Grados Canovas2,
  3. M. de los Riscos Άlvarez3,
  4. M. Pascual Pastor4,
  5. P. Moreno Fresneda5,
  6. E. Loza6,
  7. M.J. García de Yébenes y Prous6,
  8. A. Olivé Marques2,
  9. P. Carreira Delgado3,
  10. J. Narvaez García4,
  11. R. García-Vicuña5,
  12. A. Zea Mendoza1
  1. 1Rheumatology, University Hospital Ramon y Cajal, Madrid
  2. 2Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona
  3. 3Rheumatology, Hospital Universitario 12 de Octubre, Madrid
  4. 4Rheumatology, Hospital Universitario de Bellvitge, Barcelona
  5. 5Rheumatology, Hospital Universitario la Princesa
  6. 6Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain

Abstract

Background Eosinophilic fasciitis (EF) is a rare scleroderma-like disorder described in 1974 by Shulman. It is characterized by the acute onset of edema and induration of the skin and the subcutaneous tissue associated with peripheral blood eosinophilia. Deep skin biopsy shows characteristic alterations in the muscle fascia. There is no consensus regarding the treatment of the FE. Oral or intravenous glucocorticoids (GC) are usually the initial treatment with significant improvement in most cases. Immunosuppressive drugs may be associated when the response is insufficient and the most used is methotrexate (MTX). The response to MTX is usually favorable, especially in cases with concomitant morphea lesions. However, there are no studies that specifically analyze which factors predict response to treatment with this drug in EF.

Objectives To determine which demographic, clinical and laboratory baseline features are associated with remission during treatment with MTX in patients with EF.

Methods We performed an observational, retrospective (1983–2014) and multicentric study of patients with EF from 5 Spanish university hospitals. Inclusion criteria: 1) characteristic cutaneous manifestations; 2) deep biopsy with consistent changes in muscle fascia, and 3) treatment with MTX. Response to treatment with this drug is divided into: 1) complete remission (absence of symptoms and disappearance of lesions); 2) partial response (patients who develop limitation despite treatment); and 3) lack of response (persistence of symptoms and findings on examination). Statistical nonparametric tests were used for the data analysis, Kruskal Wallis for continuous variables and x2 for categorical variables.

Results 33 patients were included, 18 women (54.5%), with a mean age of 54.6 years (range 22–81) and a median duration of disease until diagnosis of 4 months (range: 1–25). Most of these patients had previously been treated with GC (97%) with insufficient response, 8 (24.2%) had previously received other Immunomodulatory drugs (hydroxychloroquine, azathioprine, cyclosporine) and 5 (15.2%) with photochemotherapy (PUVA). The median MTX dose used was 15 mg/week (range: 10–25), 16 (48.5%) cases achieved complete remission with this drug, 15 (45.5%) partial response and 2 (6%) lack of response. Patients who achieved complete remission had a mean age at diagnosis slightly higher (64), presented more frequently induration ≥50% of body surface, myalgia and associated malignancies but C-reactive protein (CRP) levels were lower. Of all the variables analyzed, only low CRP level was significantly associated with complete remission (p=0.004). Two patients in remission relapsed after discontinuation of MTX, with a favourable response to re-treatment with GC.

Conclusions The only variable that seems to be associated with remission during treatment with MTX in our series is the absence of elevated CRP. All other variables showed no significant differences, although the statistical power may be small due to the limited sample size.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.